Epics Therapeutics
Private Company
Funding information not available
Overview
EPICS Therapeutics is a Belgian biotech founded in 2018, focused on the novel field of RNA epigenetics. Its core asset is EP102, a first-in-class, potent, and selective small-molecule inhibitor of METTL3, which is now in early clinical development for multiple solid tumors including NSCLC, pancreatic, ovarian, and colorectal cancers. The company is positioning itself at the forefront of translating epitranscriptomic research into clinical therapies, with a pipeline that also includes preclinical programs in immuno-oncology and autoimmune diseases. EPICS represents a high-risk, high-reward venture targeting a new therapeutic axis complementary to existing DNA- and protein-focused treatments.
Technology Platform
Platform for discovering small-molecule modulators of RNA-modifying enzymes (epitranscriptome), with a focus on inhibitors of writers like METTL3 to reprogram RNA processing and gene expression in disease.
Opportunities
Risk Factors
Competitive Landscape
EPICS is among the first companies to advance a small-molecule METTL3 inhibitor into clinical trials, placing it in a small vanguard of firms targeting the epitranscriptome. It faces competition from other biotechs (e.g., Accent Therapeutics, Storm Therapeutics) and academic groups developing m⁶A-targeting therapies. Its competitive edge relies on the potency, selectivity, and clinical profile of EP102.